

AMENDMENTS TO THE SPECIFICATION

Please amend the specification as follows:

Please replace paragraph [068], starting at page 27, line 20, and extending to page 28, line 7, with the following amended paragraph:

[068] In one embodiment of the invention, the small molecule therapy comprises administering to the subject an effective amount of deoxynojirimycin or a deoxynojirimycin derivative. In another embodiment, the deoxynojirimycin derivative is *N*-propyldeoxynojirimycin, *N*-butyldeoxynojirimycin, *N*-butyldeoxygalactonojirimycin, ~~*N*-pentyldeoxynojirimycin~~ ***N*-pentyldeoxynojirimycin**, *N*-heptyldeoxynojirimycin, *N*-pentanoyldeoxynojirimycin, *N*-(5-adamantane-1-ylmethoxy)pentyl)-deoxynojirimycin, *N*-(5-cholesteroxypentyl)-deoxynojirimycin, *N*-(4-adamantanemethanylethylcarboxy-1-oxo)-deoxynojirimycin, *N*-(4-adamantanylethylcarboxy-1-oxo)-deoxynojirimycin, ~~*N*-(4-phenanthrylcarboxy-1-oxo)-deoxynojirimycin~~ ***N*-(4-phenanthrylcarboxy-1-oxo)-deoxynojirimycin**, *N*-(4-cholesterylcarboxy-1-oxo)-deoxynojirimycin, or *N*-(4-b-cholestanylcarboxy-1-oxo)-deoxynojirimycin.

Please replace paragraph [0163], starting at page 66, line 9, and extending to page 67, line 4, with the following amended paragraph:

[0163] Deoxynojirimycin-like compounds and related small molecules are useful in the combination therapies of the invention. *N*-butyldeoxynojirimycin (NB-DNJ or OGT 918) and derivatives thereof may be used in combination therapies of the invention for treatment of storage diseases in the glycosphingolipid pathway. The use of OGT 918 alone as an oral treatment for Gaucher's disease has been reported by Cox et al., 2000, Lancet 355, 1481-1485. OGT 918 can be used in combination therapies of the invention for any storage disease of the glycosphingolipid pathway, including Sandhoff and Tay-Sachs disease (see e.g. Jeyakumar et al., 2001, Blood 97, 327-329; Andersson et al., 2000, Biochem. Pharmacol. 59, 821-829; Jeyakumar et al., 1999, Proc. Natl. Acad. Sci USA 96, 6388-6393; and Platt et al., 1997, Science 276, 428-431).

Deoxynojirimycin derivatives include but are not limited to *N*-propyldeoxynojirimycin, *N*-butyldeoxynojirimycin, *N*-butyldeoxygalactonojirimycin, ~~*N*-pentyldeoxynojirimycin~~, ***N*-pentyldeoxynojirimycin**, *N*-heptyldeoxynojirimycin, *N*-pentanoyldeoxynojirimycin, *N*-(5-adamantane-1-ylmethoxy)pentyl)-deoxynojirimycin, *N*-(5-cholesteroxypentyl)-deoxynojirimycin, *N*-(4-adamantanemethanylethylcarboxy-1-oxo)-deoxynojirimycin, *N*-(4-adamantanylethylcarboxy-1-oxo)-deoxynojirimycin, ~~*N*-(4-phenanthrylcarboxy-1-oxo)-deoxynojirimycin~~ ***N*-(4-phenanthrylcarboxy-1-oxo)-deoxynojirimycin**, *N*-(4-cholesterylcarboxy-1-oxo)-deoxynojirimycin, or *N*-(4-b-cholestanylcarboxy-1-oxo)-deoxynojirimycin.